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EBOLA HAEMORRHAGIC FEVER VIRUS: PATHOGENESIS,  
IMMUNE RESPONSES, POTENTIAL PREVENTION
Abstract: Ebola zoonotic RNA filovirus represents human most virulent and lethal pathogens, which 
induces acute hemorrhagic fever and death within few days in a range of 60–90% of symptomatic 
individuals. Last outbreak in 2014 in West Africa caused panic that Ebola epidemic can be spread 
to other continents. Number of deaths in late December reached almost 8,000 individuals out of 
more than 20,000 symptomatic patients. It seems that only a coordinated international response 
could counteract the further spread of Ebola. Major innate immunity mechanisms against Ebola are 
associated with the production of interferons, that are inhibited by viral proteins. Activation of host 
NK cells was recognized as a leading immune function responsible for recovery of infected people. 
Uncontrolled cell infection by Ebola leads to an impairment of immunity with cytokine storm, coag-
ulopathy, systemic bleeding, multi-organ failure and death. Tested prevention strategies to induce 
antiviral immunity include: i. recombinant virus formulations (vaccines); ii. cocktail of monoclonal 
antibodies (serotherapy); iii. alternative RNA-interference-based antiviral methods. Maintaining the 
highest standards of aseptic and antiseptic precautions is equally important. Present brief review 
summarizes a current knowledge concerning pathogenesis of Ebola hemorrhagic disease and the virus 
interaction with the immune system and discusses recent advances in prevention of Ebola infection 
by vaccination and serotherapy.
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INTRODUCTION 
Ebola (EBOV) and Marburg (MARV) viruses are the members of the Filoviridae 
zoonotic RNA viruses representing the most virulent pathogens for human and 
great apes (non-human primates). EBOV is even more contagious and lethal than 
human immunodeficiency virus (HIV). EBOV and MARV induce acute hemorrhagic 
fever and death within few days in a range of 60–90% of symptomatic individuals [1].
There have been 15 Ebola outbreaks since the first outbreak of Ebola hemor-
rhagic fever (EHF) in 1976 in Africa (Sudan, Zaire). For years, in spite of extreme-
ly high mortality of EHF, Ebola considered a rare virus with local affair, draws 
little interest from funders and scientists [1, 2]. It resulted in a slow progress in 
prevention and treatment of Ebola infections.
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However, the last outbreak of EBOV in 2014 in West Africa caused panic and 
fear that Ebola epidemic can be spread to other continents including Europe and 
North America. On August 8th 2014, the WHO declared the Ebola epidemic as a 
Public Health Emergency of International Concern, its highest level of alert. Con-
tinuously increasing number of deaths in West African countries, which in De-
cember reached more than 8,000 individuals out of approximately 20,000 symp-
tomatic patients and additional few hospitalized in Europe, clearly indicated that 
only a coordinated international response, including Poland, is able to counteract 
the international spread of Ebola.
The aim of this brief review is to summarize a current knowledge concerning 
pathogenesis of Ebola hemorrhagic disease and EBOV interaction with the im-
mune system. Moreover, we will discuss recent advances in prevention of Ebola 
infection by vaccination and serotherapy. 
PATHOGENESIS OF EBOLA VIRUS DISEASE (EVD),  
FORMERLY KNOWN AS THE EBOLA HEMORRHAGIC FEVER (EHF)
Viral pathogenesis is the process by which virus infection leads to the disease. 
Pathogenic mechanisms include implantation of the virus at a body site, repli-
cation at the portal of entry, spread to and multiplication within target organs/
tissues, where disease occurs. Ability of pathogen to damage the host is related 
either to a direct cytotoxic effect, e.g. by a toxin production, or to an uncontrolled 
stimulation of the immune system and overproduction of toxic agents (e.g. ni-
tric oxide, TNF-a). Nevertheless, most viral infections are asymptomatic and sub-
clinical, indicating that the immune responses against viruses inhibit infections 
before clinical symptoms appear. In a striking contrast Ebola virus infection is 
characterized by an extremely high pathogenicity with a fatal outcome [2, 3]. Only 
in a minority of cases the infection results in a transient flu-like syndrome and 
full recovery, whereas in majority of infected population, EBOV evokes severe ill-
ness associated with fever, myalgia, general malaise, gastro-intestinal symptoms 
(vomiting and diarrhea), conjunctival hemorrhage and encephalopathy [3, 4]. Why 
EBOV shows such extreme virulence and pathogenicity?
The EBOV genome is covered by a lipid envelope that facilitates virus entry 
into host cells. Most viruses have an affinity for specific tissues. Importantly, in 
contrast to tissue specificity/tropism of human viruses, EBOV, the zoonotic virus, 
is able to replicate in a wide range of the human cells including: immune cells, 
endothelial cells, fibroblast, hepatocytes, and adrenal cells [5]. It is clear that viral 
envelope glycoprotein (GP) is responsible for both receptor binding and fusion of 
the viral envelope with the host membrane [5]. Moreover, it has been estimated 
that Ebola virus primarily targets macrophages and dendritic cells and, subse-
quently, endothelial cells through a mucin-like domain of GP [6, 7]. Therefore, 
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EVD first disables the immune system and then, in turn, affects the vascular 
system. It results in disseminated intravascular coagulation, hemorrhage, shock, 
circulation failure and death. The virus also affects other organs/tissues, leading 
to a failure of liver (multi-focal necrosis, decreased production of clotting factors), 
adrenal glands (that stop the production of steroids and corrupt the regulation of 
blood pressure) and gastro-intestinal tract (diarrhea) [3]. All these clinical symp-
toms of EVD are associated with uncontrolled dissemination and replication of the 
virus in infected host but precise mechanisms are still not fully defined. Current 
state of knowledge points to the following scenario of the events:
• At a gate of infection — sentinel immune cells, macrophages and dendrit-
ic cells are early targets of EBOV. Extensive infection of these cells leads to 
overproduction of inflammatory mediators and chemokines such as IL-1, IL-6, 
IL-8, TNF-a, monocyte chemotactic protein-1 and eotaxins (eosinophil chemo-
attractants). This “cytokine storm” is responsible for attracting inflammatory 
cells (neutrophils, eosinophils) to the infected tissues, inducing coagulopathy 
and increasing endothelial permeability [8].
• Then the virus spreads to secondary lymphoid organs and liver where massive 
replication takes place and other cells are infected. At this stage EBOV infec-
tion is associated with disseminated intravascular coagulation which leads to 
a consumption of coagulation factors, fibrin deposition, microtrombin produc-
tion and, ultimately, to systemic bleeding [3].
• Finally, multi-focal necrosis of hepatocytes and other tissue damage resulting 
from direct cytopathic effects and from the host response leads to multi-organ 
failure, terminal shock and death (Fig. 1).
Fig. 1. Cascade of pathological events associated with EBOV infection  
and the development of severe Ebola hemorrhagic fever (EHF).
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EBOV INFECTION AND THE IMMUNE RESPONSE
The outcome of each step of viral infection, starting from the implantation of vi-
rus at the gate of entry, through local replication, dissemination (viraemia), mul-
tiplication in targeted organs, onset of disease and finally the recovery (shedding 
of virus) or death, depends on the balance between two factors, virus and host 
defenses. At each step of virus progression through the body, the local (innate 
immunity) and systemic recovery mechanisms (specific humoral and cellular im-
munity) are activated. However, majority of EBOV infections leads to a fatal out-
come that is in striking contrast with the effective control of other viral infections 
associated with the balanced immune response [8].
As stated above, inflammatory immune cells (macrophages) and antigen pre-
senting cells (dendritic cells) are the first targets of EBOV, and it results in an 
impaired innate and adaptive immune response that facilitates uncontrolled viral 
replication and dissemination.
Major mechanisms of the innate immunity against viral implantation and local 
replication are associated with the production of type 1 interferons (IFNa/b) [9]. 
Unfortunately, EBOV, as well as other filoviruses, encodes two different proteins 
(VP24, VP35), components of the viral nucleocapsid, that block host interfer-
ons production and signaling. VP24 directly inhibits IFNa/b and IFNg signaling 
through an interaction with STAT1 and blocking its nuclear import. On the oth-
er hand, Ebola VP35 inhibits the production of IFNa/b by several mechanisms, 
as described elsewhere [7, 9]. This total inhibition of interferon-dependent in-
nate immunity by Ebola VP35 and VP24 proteins is strongly correlated with an 
increased virulence of filoviruses and has also an impact on other immune re-
sponses in the severe EVD.
Evasion of the immune response by Ebola virus, except for disabling of the 
IFN-system, is also associated with an impaired humoral and cellular adaptive 
immunity [7, 10]. It has been documented that infection of macrophages and 
dendritic cells, primarily antigen presenting cells (APC), contributes to the in-
flammation, coagulopathy and ineffective immune response characteristic for 
a fatal outcome of Ebola hemorrhagic fever. One of the detrimental consequences 
of APCs infection for host immunity is a massive apoptosis of T cells (T helper 
and T cytotoxic cells) and NK cells [1]. In addition, the production of specific an-
ti-virus antibodies is inhibited [10]. Fatal EHF is characterized by the absence of 
specific IgG and by barely detectable IgM. On the contrary, an early and strong 
humoral response is correlated with survival in symptomatic patients [1, 3].
Taken together, these reports suggest that deregulated and impaired adaptive 
immunity accompanied with the “cytokine storm” is characteristic for the severe 
Ebola infection and indicates that vaccination is the best strategy to prevent the 
disease. 
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ADVANCES IN EVD IMMUNE PREVENTION 
Owing to a very high mortality of infected patients, difficulty in elaboration of 
treatment ensuring full recovery and necessity for the professional health care 
for symptomatic individuals, fast elaboration of efficient and commonly available 
prevention method(s) should be the center of urgent attention. Furthermore, lack 
of awareness leading to risky behavior of unqualified people and professionals as 
well as ignorance of standard assessment procedures and failure of public health 
system (including crowded emergency rooms, delay in isolation and long-lasting 
diagnostic procedures, and, finally, low number of health staff), all results in 
unexpectedly fast spreading of EBOV epidemic [11–13]. Activation of host im-
mune defense mechanisms, specific antiviral immunity by vaccination especially, 
seems to be the best way to assure resistance of population to EBOV infection. 
However, the main problem is the virus capability to avoid immune response. 
As mentioned previously, EBOV infected host cells produce protein inhibitors of 
interferons (VP24 and VP35) encoded by viral genetic material. Both inhibitors 
block production of endogenous interferons as well as intracellular signalization 
pathways activated by interferons even if delivered in therapy [4, 9]. 
At the beginning, the alarming problem was also a very weak effort of the 
World Health Organization (WHO) to prevent the spread of current Ebola out-
break. As an example, it could be pointed out that when the GlaxoSmith-Kline 
(GKS) contacted the WHO to show their vaccine in March at the start of this 
outbreak, no one expressed much interest. The response was “thanks, we will get 
back to you” [14]. Fortunately, now the situation has changed. On 3rd of Octo-
ber the WHO reported 7470 cases of infection and 3431 deaths [15]. However, in 
the main three affected countries (Guinea, Sierra Leone and Liberia) the number 
of cases is still growing [16]. Further, on December 31th the number of deaths 
reached 7905 people among 20.206 infected individuals. In this Ebola outbreak 
all that can be offered is the isolation and quarantine instead of effective vac-
cines and treatment. During current outbreak approximately 150 medical doctors 
and nurses died and 240 members of medical staff were infected as estimated 
on September 12th [11], and the still growing numbers in December reached 382 
and 672, respectively, which significantly influenced the health care system and 
public attitudes to EBOV progressive epidemic [17]. Because of such unexpected 
situation the WHO announced that compassionate use of experimental therapies 
is ethically justified, even if they had not yet been tested in humans, arguing 
that an exceptional crisis requires an exceptional response [11]. At the time of 
growing Ebola epidemic problem in the middle of July 2014 scientists from re-
search laboratories working with EBOV were strongly against the use of labo-
ratory methods to control Ebola invasion. They were still waiting for an official 
permission rather than forgiveness in case of failed results of treatment. But now 
they are frustrated. The worst Ebola outbreak since the current one killed 600 
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people. At present a representative for the WHO claimed that using the vaccines 
now would not be ethical, feasible nor wise [18]. Such feelings of helplessness 
and unresponsiveness during a new huge outbreak of Ebola epidemic infection 
was typical before the August 8th since when the WHO declared the crisis and 
threatening situation with the highest level of alert.
Based on the study provided by Gire at al. it is suggested that the lineage of 
the three most recent outbreaks of Ebola infections and EVD (Democratic Re-
public of Congo 2007–2008, and Guinea and Sierra Leone both 2014) all derived 
from a common ancestor at roughly the same time around 2004, which supports 
the hypothesis that each outbreak represents an independent zoonotic event from 
the same genetically diverse viral population in its natural reservoir [19]. Although 
according to the WHO description from September 2014, the last outbreak of 
EVD is evidenced as Zaire species (and not two others Sudan and Bundibungyo 
Ebola viruses that were formerly associated with large outbreaks in Africa) [20]. 
Several tested preventing strategies (in nonhuman primate models) have been 
introduced into clinical investigation. These include methods based on the use 
of: i. recombinant formulations (based on adenovirus, vesicular stomatitis virus 
(VSV), rabies virus); ii. cocktail of monoclonal antibodies (such as ZMapp); iii. 
alternative RNAi-based approaches (such as TKM-Ebola and antisense-based e.g. 
AVI-7537) [3]. Presently, it is also known that seven independent proteins are 
encoded by EBOV genome. Starting from 5’ end they include nucleocapsid pro-
tein (NP), VP35 (interferon antagonist) VP40, glycoprotein (GP), VP30, VP24 (in-
terferon antagonist) and the last one, RNA-dependent RNA Polymerase L protein, 
which is localized at the 3’ end of the codon. The antiviral vaccine approach is 
dedicated mainly against GP, mediating internal fusion of the virus with targeted 
host cells (mainly monocytes/macrophages and dendritic cells, but also cells of 
interstitial organs that could be used in post-mortal infection confirmatory test-
ing) [21] suspected to be dependent on TIM-1 (T-cell immunoglobulin mucin-1) 
domain expressed on mucosal membranes [9]. The Zaire EBOV glycoprotein (ZGP) 
structure expresses 164 amino acids long peptide (MFL) that contains furin site 
and internal fusion loop recognized as a main contributor of immunogenicity of 
glycoprotein determinant domain of Zaire EBOV. The MFL structure of both Zaire 
(ZGP) and Sudan (SGP) Ebola virus Glycoprotein Structures is introduced as 
a leading structure in the single recombinant VSV (rVSV) vector of bivalent vac-
cines against EVD [21]. The first activity of rVSV vaccine is the activation of neu-
tralizing function of antibodies involved in clearing of Ebola viraemia and blockade 
of introducing the EBOVs into host cells. The data obtained from experiments on 
the efficiency of GP-expressing recombinant adenovirus vaccine in animal models 
of Ebola viral infections suggest that T CD8+ dependent cytotoxic cellular immune 
response plays the key protective role. In humans that survived EVD, the activa-
tion of host NK cells immune response against viral invaders was recognized as 
leading immune function responsible for recovery. Thus, the vaccine should be 
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able to induce cellular immune response, and this promotes methods based on 
modified viral vectors resembling infectious and replicating living viruses. On the 
other hand, due to the extraordinary fast multiplication of EBOV after host cell 
invasion there is the need to block the TIM-1 dependent interaction of virus with 
cell membrane by actively (vaccines) or passively (monoclonal antibodies) delivered 
neutralizing antibodies against GP. The first two clinical trials of filovirus vaccines 
showed the possibility of successful induction of filovirus-specific humoral and 
cellular responses directed against EBOV. The latter, T dependent response, was 
estimated in flow cytometry and ELISPOT assays [10]. The aforementioned meth-
ods are now considered the standards for evaluation of vaccination efficiency. It 
should also be noted that vaccination initially is dedicated for health care work-
ers (12.000 people according to the WHO) as they are at a high risk of exposure 
and provide a critical service in fighting the EBOV outbreak [22, 23]. 
At the moment, the strongest activities of pharmaceutical companies are fo-
cused on the production of Ebola vaccines. Aforementioned Ebola vaccine made 
by GlaxoSmith-Kline (GSK) in Rixensart, Belgium, is the furthest along, and has 
entered phase I human trials on September 2nd. By the end of 2014, GSK commit-
ted to manufacture up to 10,000 doses of the vaccine, containing Ebola surface 
protein stitched into attenuated chimpanzee adenovirus [24]. The vaccine could be 
given to health workers as soon as in November 2014 [14]. Initially it was even 
estimated that GSK vaccine production level would achieve even up to 100,000 
doses per month [14]. Now the chance to multiply the production is estimated 
up to 230,000 doses by April 2015 and even 1 million by December 2015 [25]. 
Another company which already prepared 1,500 doses of the Ebola vaccine is 
NewLink Genetics of Ames from Iowa collaborating with Canadian National In-
stitute of Public Health. The vaccine is based on a crippled vesicular stomatitis 
virus (VSV), which infects livestock, with the introduced gene encoding EBOV 
surface protein. Profectus BioScience from Maryland prepares a similar vaccine 
that should be ready for human testing next June. However, each company needs 
a commitment from a fund-raiser before it can scale production from the planned 
5,000 to 20,000 doses. Noteworthy is the fact that VSV vaccine possibly could also 
be used in post-exposure condition as it happened in case of accidental contact 
of a German researcher with EBOV in 2009 [18], although there is no evidence 
yet for the effectiveness and pertinence of such procedure. 
Monoclonal antibodies against EBOV GP were the first experimental thera-
peutics used for symptomatic medical professionals during current outbreak. 
Attempts to use serotherapy as a first step prevention method after contact with 
EBOV were also made. Combination of monoclonal antibodies called ZMapp was 
shown to be able to rescue 100% of rhesus macaques, when treatment was initi-
ated up to 5 days post contact with EBOV. The high fever, viraemia and advanced 
EVD indicated by elevated liver enzymes, mucosal haemorrhages and generalized 
petechiae could be reversed leading to a full recovery. ELISA and neutralizing 
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antibody assays demonstrated that ZMapp is cross-reactive with Guinea variant 
of Ebola [26]. ZMapp, made by Mapp Biopharmaceutical of San Diego, Califor-
nia, contains three monoclonal antibodies produced in tobacco plants. The pro-
cessing from plants to biologically active product takes a few months and only 
ten doses were yet prepared, out of which seven were used to treat seven Ebola 
infected human individuals [14]. 
The U.S. Congress supported the institution named HHS’s Biomedical Advanced 
Research and Development Authority (BARDA) and established to speed up the 
development of treatment methods and vaccines for emergencies with 58 million 
USD dedicated for defense against EBOV. BARDA contacted two other outfits 
that can possibly produce the antibodies against Ebola in tobacco plants or in Chi-
nese hamster ovary cells — the standard system for monoclonal antibodies process-
ing. However, according to manufacturer reports the efficiency of production will 
never be as high as that of vaccines [14] despite the fact that at present over 
25 laboratories from 7 countries are involved in the production of monoclonal 
antibodies against EBOV. This project has already consumed 28 million USD 
founded by the National Institute for Allergy and Infectious Diseases (NIAID) [18].
Most studies have been funded by the U.S. Government in response to wor-
ries about biowarfare and bioterrorism. The compound identified by U.S. Army 
researchers and based on RNA interference is in the course of development of 
Tekmira Pharmaceutical Corporation. But at the beginning of July 2014 the Food 
and Drug Administration held it on the first trial phase because of the need to 
clarify the protocol to protect safety of participants. The U.S. Army Medical Re-
search Institute of Infectious Diseases developed a project on a powerful nucle-
oside analog, which is now stopped. Similarly, the promising project concerning 
anti-sense-based compound tested by Sarepta Therapeutics in Cambridge, Massa-
chusetts, has unsuccessfully ended after Pentagon stopped funding in 2012 [18]. 
Nevertheless, RNAi-based methods are now abandoned and the financial support 
is dedicated to work on vaccines and monoclonal antibodies. There is the infor-
mation that new studies on EBOV vaccines start soon in Switzerland and Ger-
many. According to Norwegian Institute of Public Health the total cost of vaccine 
development will reach 73 million USD and next 78 million USD will be con-
sumed by vaccination of population at risk [23].
CONCLUSIONS
All the above data clearly indicate that the evasion of the immune response by 
EBOV is responsible for a fatal outcome of Ebola virus disease. Better under-
standing of mechanisms of the virus interaction with the immune system and 
a proper prevention (vaccines, at present undergoing final phase of clinical trial) 
is a great hope for the future combat against Ebola. 
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However, it should be highlighted that in the overall Ebola outbreak per-
spective prevention plays the most important role, not only in the form of 
vaccination and serotherapy, but also as maintaining the highest standards 
of aseptic and antiseptic precautions. 
Finally, we would like to conclude to follow the Science (12.08.2014) [11]: “Let 
us hope that this is the last Ebola outbreak where all we have to offer is isola-
tion and quarantine, instead of a vaccine and treatment.”
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